Scholar Rock shifts manufacturing plan to keep SMA drug on track

The U.S. Food and Drug Administration (FDA) has once again found problems at a manufacturing facility that was included on Scholar Rock‘s application seeking approval of apitegromab, its experimental muscle-strengthening agent for spinal muscular atrophy (SMA). In light of the continued issues at the facility, Scholar Rock said it will remove that facility from its […] The post Scholar Rock shifts…